How this report was compiled
Figures come from the written quotes our medical office issued to international patients during 2026. A quote enters the dataset only after a medical file review, because pre-review estimates are not comparable.
Ranges are reported rather than averages. An average would hide the fact that the same diagnosis can require one infusion or a multi-session protocol, and averaging across those produces a number that describes nobody.
- Unit of analysis: one issued written quote
- Currency: euro, converted at the rate stated on the quote
- Excluded: enquiries declined before review, and travel or accommodation costs
- Rounding: ranges rounded to the nearest €500
What each protocol costs and why it moves
| Protocol | Quote range | Main driver | Typical sessions |
|---|---|---|---|
| Single-condition MSC | €6,000 – €12,000 | Cell dose and route | 1 |
| Multi-session MSC | €12,000 – €20,000 | Repeat doses over 3–12 months | 2 – 3 |
| MSC plus exosome | €14,000 – €25,000 | Added product and sessions | 2 – 4 |
| Exosome only | €3,500 – €8,000 | Vial count and route | 1 – 3 |
| Hospital admission and imaging | €800 – €3,000 | Day case vs inpatient | — |
What is included, and what clinics commonly exclude
| Item | Included in our quote | Commonly excluded elsewhere |
|---|---|---|
| Cell manufacture | Yes | Rarely itemised |
| Release testing certificate | Yes | Often not provided |
| Hospital administration | Yes | Frequently billed separately |
| Imaging and baseline labs | Yes, where protocol requires | Frequently billed separately |
| Year-1 follow-up reviews | Yes | Often charged per visit |
| Flights and hotel | No | No |
What patients should verify before paying
- Cell type, cell dose and delivery route, stated numerically
- Whether a release certificate for your batch will be issued
- Which hospital costs are inside the quote
- How many sessions the price covers and what a repeat costs
- The follow-up schedule and who provides it
- Deposit, refund and rescheduling terms
Limitations of this edition
This is a single-centre dataset. It describes what one licensed Istanbul centre quoted in 2026, not a national or market average, and it should not be cited as one.
Comparisons with other providers in this report rely on their published price pages and patient-reported quotes, which we cannot audit.
Questions about this report
How to cite this report
StemCell Longevita (2026). International Patient Cost Transparency Report 2026. Istanbul: StemCell Longevita medical office.
Reuse is permitted under CC BY 4.0 with a link back to https://stemcelllongevita.com/reports/international-patient-cost-transparency-2026. Corrections: contact the medical office.
Compiled by the StemCell Longevita medical office. Medically reviewed by Prof. Dr. Erdal Karaöz Team. Published . Method and definitions: editorial and evidence policy. This report is information about our own process and pricing, not medical advice and not a promise of clinical benefit.